Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma

被引:32
作者
Yoshimura, K
Arai, Y
Fujimoto, H
Nishiyama, H
Ogura, K
Okino, T
Ogawa, O
机构
[1] Kurashiki Cent Hosp, Dept Urol, Okayama, Japan
[2] Cent Hosp, Natl Canc Ctr, Dept Urol, Tokyo, Japan
[3] Kyoto Univ, Dept Urol, Kyoto, Japan
[4] Kurashiki Cent Hosp, Dept Clin Pathol, Okayama, Japan
关键词
renal pelvic carcinoma; transitional cell carcinoma; prognosis; invasion patterns; parenchymal invasion;
D O I
10.1002/cncr.10609
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Pathologic T3 renal pelvic transitional cell carcinoma exhibits various patterns of invasion. The authors investigated the prognostic impact of three patterns of invasion of pT3 renal pelvic transitional cell carcinoma. METHODS. Of 212 patients who under-went surgery for renal pelvic transitional cell carcinoma, 70 with pT3 disease were eligible for the main analyses. The candidate predictors of prognosis included patient age, gender, lesion laterality, tumor grade, perioperative cisplatin-based systemic chemotherapy, lymph node involvement, vascular involvement, and patterns of invasion. Invasion patterns were classified as fat invasion, ductal involvement, or parenchymal invasion. RESULTS. Mean postoperative followup was 33.5 months (range, 1-136 months). On univariate analysis, gender, lymph node involvement, vascular involvement, and extensive parenchymal invasion each had a significant impact on the cause 3 specific survival rate. A multivariate analysis using Cox stepwise regression revealed that extensive parenchymal involvement was the strongest prognostic predictor (P = 0.0004, hazard ratio = 5.59). Lymph node involvement (P = 0.0175, hazard ratio 3.14) and gender (P = 0.0361, hazard ratio = 2.42) were other weaker predictors. Statistically, pT3 disease without extensive parenchymal invasion had a prognosis similar to that of lower stage disease, and pT3 disease with extensive parenchymal invasion had a prognosis similar to that of pT4 disease. CONCLUSIONS. Extensive parenchymal invasion has a strong prognostic impact in renal pelvic transitional cell carcinoma. pT3 disease should be subclassified into two separate entities, that with and that without extensive parenchymal invasion, in view of prognosis. (C) 2002 American Cancer Society.
引用
收藏
页码:3150 / 3156
页数:7
相关论文
共 32 条
[21]   MANAGEMENT OF HIGH-GRADE TRANSITIONAL CELL-CANCER OF THE UPPER URINARY-TRACT [J].
MURPHY, DM ;
ZINCKE, H ;
FURLOW, WL .
JOURNAL OF UROLOGY, 1981, 125 (01) :25-29
[22]   TRANSITIONAL CELL-CARCINOMA OF RENAL PELVIS [J].
NOCKS, BN ;
HENEY, NM ;
DALY, JJ ;
PERRONE, TA ;
GRIFFIN, PP ;
PROUT, GR .
UROLOGY, 1982, 19 (05) :472-477
[23]   Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas [J].
Özdemir, E ;
Kakehi, Y ;
Okuno, H ;
Yoshida, O .
JOURNAL OF UROLOGY, 1999, 161 (04) :1359-1363
[24]   Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer [J].
Özer, E ;
Mungan, MU ;
Tuna, B ;
Kazimoglu, H ;
Yörükoglu, K ;
Kirkali, Z .
UROLOGY, 1999, 54 (01) :50-55
[25]   Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement [J].
Pagano, F ;
Bassi, P ;
Ferrante, GLD ;
Piazza, N ;
Abatangelo, G ;
Pappagallo, GL ;
Garbeglio, A .
JOURNAL OF UROLOGY, 1996, 155 (01) :244-247
[26]  
Papathoma AS, 2000, ANTICANCER RES, V20, P2009
[27]   SLOW N-ACETYLATION GENOTYPE IS A SUSCEPTIBILITY FACTOR IN OCCUPATIONAL AND SMOKING-RELATED BLADDER-CANCER [J].
RISCH, A ;
WALLACE, DMA ;
BATHERS, S ;
SIM, E .
HUMAN MOLECULAR GENETICS, 1995, 4 (02) :231-236
[28]   PROSTATIC INVOLVEMENT BY TRANSITIONAL CELL-CARCINOMA - PATHOGENESIS, PATTERNS AND PROGNOSIS [J].
SCHELLHAMMER, PF ;
BEAN, MA ;
WHITMORE, WF .
JOURNAL OF UROLOGY, 1977, 118 (03) :399-403
[29]   Gender-specific effects of NAT2 and GSTM1 in bladder cancer [J].
Schnakenberg, E ;
Lustig, M ;
Breuer, R ;
Werdin, R ;
Hübotter, R ;
Dreikorn, K ;
Schloot, W .
CLINICAL GENETICS, 2000, 57 (04) :270-277
[30]  
Sobin LH, 1997, TNM CLASSIFICATION M